Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Oct 8;25(1):1248.
doi: 10.1186/s12879-025-11700-0.

Clinical outcomes of dolutegravir treatment in people living with HIV in Brazil: protocol for the CODE cohort

Carlos Brites  1 , Estela Luz  2 , Cristiani Stelitano  2 , Fabianna Bahia  3 , Marcus Vinícius Guimarães de Lacerda  4 , Aline Ramalho  5 , Sandra Wagner Cardoso  6 , Valdez Madruga  7 , Tânia Reuter  8 , Alexandre Naime Barbosa  9 , Rosa Dea Sperhack  10 , Monica Baumgardt Bay  11 , Tâmara Newman  12 , Karen Morejon  13 , Maria Patelli  14 , Fábio Leal  15 , Eduardo Sprinz  16 , Cristina Murray-Krezan  17 , Mary Carmody  18 , Jess Anderson  19 , Alejandro Aragon  19 , Benjamin Chase  19 , Roberto Zajdenverg  20 , Bryn Jones  21 , Fatima Dutra  19 , Kimberly Page  19
Affiliations
Observational Study

Clinical outcomes of dolutegravir treatment in people living with HIV in Brazil: protocol for the CODE cohort

Carlos Brites et al. BMC Infect Dis. .

Abstract

The Clinical Outcomes of Dolutegravir Treatment in People Living with HIV in Brazil (CODE) cohort study is a multicenter, prospective, observational study designed to evaluate the safety and efficacy of Dolutegravir (DTG)-based antiretroviral therapy (ART) among people living with HIV across diverse settings in Brazil. With the recent global shift towards DTG as a preferred option for first-line ART, particularly in low- and middle-income countries, there is vital need for comprehensive real-world data to inform its widespread use. CODE aims to fill this knowledge gap by assessing the clinical outcomes of both ART-naïve and ART-experienced patients initiating DTG-based regimens, as well as those who have switched from non-DTG-based ART. The primary objective of this study is to determine the proportion of patients who discontinue DTG due to any adverse events, specifically focusing on metabolic and psychiatric outcomes. Secondary objectives include evaluating the rates of virological suppression, the occurrence of immune reconstitution inflammatory syndrome (IRIS), changes in body mass index (BMI), and the development of HIV drug resistance. The CODE cohort will enroll approximately 5000 participants from multiple clinical sites across Brazil, including 2500 ART-naïve individuals, 1000 patients switching to DTG-based regimens for various reasons, and a comparator group of 1500 individuals who initiated non-DTG-based ART between 2013 and 2016, before DTG was available in the country. Participants will be followed for up to 36 months, with data collection points at baseline, 6, 12, 24, and 36 months. This study is expected to generate critical insights into the long-term outcomes associated with DTG-based ART, particularly in real-world settings that reflect the complexities of routine clinical care. By providing robust data on the effectiveness and safety of DTG in a diverse patient population, the CODE study aims to contribute to the optimization of HIV treatment strategies both in Brazil and globally.Key words: HIV-1, Dolutegravir, Outcomes, Brazil.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Ethical approval has been obtained from the IRBs at each participating site, and all participants will provide written informed consent prior to enrollment. Consent for publication: Not aplicable. Competing interests: CB: Research grants: CNPq, GSK, Pfizer, Janssen. All but CNPq grants were awarded to Fundação Bahiana de Infectologia; Speaker and Advisory board (Gilead, GSK, MSD); SCW: Advisory Boar (ViiV); VM: Speaker (GSK, Gilead, Janssen); ANB: Speaker (Abbvie, Amgen-Bergamo, Astrazeneca, Boehringer Ingelheim, Celltrion, Dr. Reedys, Eurofarma, Gilead, GSK-ViiV, Janssen, Knigth Therapeutics, Moderna, MSD, Pfizer, Procter Gamble, Roche, Sanofi Pasteur, S. C. Johnson Johnson, Takeda, e Wyeth); KP: Has received research grants from the U.S. National Institutes of Health, and U.S. Centers for Disease Control and Prevention. All grants were awarded to the University of New Mexico. RZ: GSK employee; BJ: ViiV Healthcare employee.

Figures

Fig. 1
Fig. 1
Clinical sites for the CODE Study
Fig. 2
Fig. 2
Code Consort Diagram (as of 01 September 2024)
See this image and copyright information in PMC

References

    1. Ministerio de Saude B. Protocolo Clínico e Diretrizes Terapêuticas para Manejo da Infecção pelo HIV em Adultos, 2024 [Internet]. 2024. Available from: https://bvsms.saude.gov.br/bvs/publicacoes/ pcdt_manejo_hiv_adultos_modulo1.pdf. Accessed in 06 Sept 2024.
    1. World Health Organization. WHO recommends dolutegravir as preferred HIV treatment option in all populations. 2023. Available from: https://www.who.int/news/item/22-07-2019-who-recommends-dolutegravir-as-.... Accessed September 06, 2024.
    1. Aprilianti S, Utami AM, Suwantika AA, Zakiyah N, Azis VI. The cost-effectiveness of dolutegravir in combination with Tenofovir and lamivudine for HIV therapy: A systematic review. Clinicoecon Outcomes Res. 2024;16:25–34. - PMC - PubMed
    1. Wijting I, Wit F, Rokx C. ATHENA National observational HIV cohort. ATHENA National observational HIV cohort. - PMC - PubMed
    1. Gaillet A, Calin R, Flandre P, Tubiana R, Valantin M-A, Caumes E, et al. Increased risk of IRIS-associated tuberculosis in HIV-infected patients receiving integrase inhibitors. Infect Dis now. 2021;51(1):90–3. - PubMed

Publication types

MeSH terms

LinkOut - more resources